- FAMAR CEO Konstantinos Rengis is stepping down after 16 years with the company, including four years as CEO, effective September 29, 2025.
FAMAR has announced a leadership transition as Konstantinos Rengis steps down as CEO for personal reasons, effective September 29, 2025. Rengis has been with the company for 16 years, serving as CEO for the past four. During his tenure, he guided FAMAR through multiple ownership transitions, improved operations, and strengthened customer service.
Taking over the role is Dr. Riku Rautsola, who has served as a non-executive member of FAMAR’s Board of Directors and advised MidEuropa during its acquisition of the company last year. Rautsola has extensive experience in the pharmaceutical, biotech, and CDMO sectors, having held senior executive and CEO positions at multiple companies.
Under Rautsola’s leadership, FAMAR will continue to serve its global customer base, expand production capacity, accelerate development partnerships, and invest in its workforce. He will also remain a member of the company’s Board of Directors.
Rengis will continue to support FAMAR in a senior advisory role, focusing on strategic customer relationships and engagement. His ongoing involvement aims to ensure continuity during the leadership transition.
“We thank Kostas Rengis for his many years of dedicated service, and we extend a warm welcome to Riku Rautsola as he leads FAMAR in this next chapter of growth and transformation.”
Matthew Strassberg, Partner and Head of Healthcare at MidEuropa
